Esomeprazole magnesium hydrate
|
- $102 - $426
- Product name: Esomeprazole magnesium hydrate
- CAS: 668985-31-7
- MF: C34H38MgN6O7S2
- MW: 731.14
- EINECS:
- MDL Number:
- Synonyms:(S)-Omeprazole magnesium hydrate;Esomeprazole magnesium hydrate >=98% (HPLC), powder;(S)-5-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole, magnesium salt hydrate
3 prices
Selected condition：
Brand
- Chemenu
- Sigma-Aldrich
Package
- 50mg
- 250mg
- ManufacturerChemenu
- Product numberCM161688
- Product description(S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole,magnesiumsalthydrate 95%
- Packaging250mg
- Price$426
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberE7906
- Product descriptionEsomeprazole magnesium hydrate ≥98% (HPLC), powder
- Packaging50mg
- Price$102
- Updated2024-03-01
- Buy
- ManufacturerSigma-Aldrich
- Product numberE7906
- Product descriptionEsomeprazole magnesium hydrate ≥98% (HPLC), powder
- Packaging250mg
- Price$414
- Updated2024-03-01
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Chemenu | CM161688 | (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole,magnesiumsalthydrate 95% | 250mg | $426 | 2021-12-16 | Buy |
| Sigma-Aldrich | E7906 | Esomeprazole magnesium hydrate ≥98% (HPLC), powder | 50mg | $102 | 2024-03-01 | Buy |
| Sigma-Aldrich | E7906 | Esomeprazole magnesium hydrate ≥98% (HPLC), powder | 250mg | $414 | 2024-03-01 | Buy |
Properties
storage temp. :2-8°C
solubility :DMSO: ≥5mg/mL
form :powder
color :white to off-white
optical activity :[α]/D -124 to -136°, c = 0.5 in methanol
solubility :DMSO: ≥5mg/mL
form :powder
color :white to off-white
optical activity :[α]/D -124 to -136°, c = 0.5 in methanol
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|